REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that company management will participate in two upcoming investor conferences in August.
Details of the events are as follows:
BTIG Virtual Biotechnology Conference, August 5-6, 2024
- The Adicet Bio team will be available for one-on-one meetings during the conference. Please contact your sales representative at BTIG to register for a meeting with the company.
Canaccord Genuity Global Growth Conference, August 13-14, 2024, Boston, MA
- Chen Schor, President and Chief Executive Officer will participate in a fireside chat on August 13, 2024 at 10:30am ET.
The live audio webcast of the Canaccord Genuity fireside chat can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
